Morrissey E C, McDonald B R, Rabetoy G M
Department of Internal Medicine, Brookside Hospital, Richmond, CA, USA.
Am J Kidney Dis. 1997 Apr;29(4):615-9. doi: 10.1016/s0272-6386(97)90346-2.
A case of significant proteinuria occurred as a result of bilateral renal vein thrombosis secondary to dehydration, which resolved after treatment with urokinase. The patient developed nausea and vomiting from viral gastroenteritis with subsequent volume contraction. He later noted the onset of aching lower abdominal and flank pain. On admission, he was noted to have a serum creatinine of 1.7 mg/dL, and 4+ proteinuria on urinalysis. A 24-hour urine collection showed 2.34 g protein. A renal venogram showed bilateral renal vein thrombosis (RVT) without involvement of the inferior vena cava. Therapy was initiated with heparin at 1,000 U/hr, followed by intravenous (IV) urokinase, 4,400 U/kg bolus, followed by 4,400 U/kg/hr with continuous infusion for 12 hours. A repeat renal venogram done at this time showed partial resolution of thrombosis bilaterally. A second 12-hour infusion of urokinase at 5,000 U/kg/hr was performed; at this time, the patient reported resolution of his flank and abdominal pain. A repeat 24-hour urine collection showed 60 mg protein with a normal creatinine clearance. Levels of antithrombin III, protein C, and protein S were all normal. A renal biopsy was performed and showed normal histology on light, immunofluorescent, and electron microscopic evaluation. The patient has done well on no therapy and has had no recurrence of thrombosis or proteinuria after 2.5 years. This is a US government work. There are no restrictions on its use.
一例因脱水继发双侧肾静脉血栓形成导致大量蛋白尿的病例,经尿激酶治疗后缓解。患者因病毒性肠胃炎出现恶心、呕吐,随后出现容量收缩。他后来注意到下腹部和侧腹疼痛。入院时,发现他的血清肌酐为1.7mg/dL,尿检显示4+蛋白尿。24小时尿蛋白定量显示为2.34g。肾静脉造影显示双侧肾静脉血栓形成(RVT),未累及下腔静脉。治疗开始时给予肝素1000U/hr,随后静脉注射尿激酶,4400U/kg推注,然后以4400U/kg/hr持续输注12小时。此时重复进行的肾静脉造影显示双侧血栓部分溶解。第二次以5000U/kg/hr的剂量静脉输注尿激酶12小时;此时,患者报告侧腹和腹痛缓解。再次进行24小时尿蛋白定量显示尿蛋白60mg,肌酐清除率正常。抗凝血酶III、蛋白C和蛋白S水平均正常。进行了肾活检,光镜、免疫荧光和电镜评估显示组织学正常。该患者未接受治疗情况良好,2.5年后未出现血栓形成或蛋白尿复发。这是美国政府的工作成果。其使用不受限制。